


Wiley Series in Drug Discovery and Development

Binghe Wang, Series Editor

EDITED BY MING HU • XIAOLING LI

# ORAL BIOAVAILABILITY AND DRUG DELIVERY

FROM BASICS TO  
ADVANCED CONCEPTS  
AND APPLICATIONS



WILEY



## **Oral Bioavailability and Drug Delivery**

# Wiley Series in Drug Discovery and Development

Binghe Wang, Series Editor

*Drug Delivery: Principles and Applications*

Edited by Binghe Wang, Teruna Siahaan, and Richard A. Soltero

*Computer Applications in Pharmaceutical Research and Development*

Edited by Sean Ekins

*Glycogen Synthase Kinase-3 (GSK-3) and Its Inhibitors: Drug Discovery and Development*

Edited by Ana Martinez, Ana Castro, and Miguel Medina

*Aminoglycoside Antibiotics: From Chemical Biology to Drug Discovery*

Edited by Dev P. Arya

*Drug Transporters: Molecular Characterization and Role in Drug Disposition*

Edited by Guofeng You and Marilyn E. Morris

*Drug-Drug Interactions in Pharmaceutical Development*

Edited by Albert P. Li

*Dopamine Transporters: Chemistry, Biology, and Pharmacology*

Edited by Mark L. Trudell and Sari Izenwasser

*Carbohydrate-Based Vaccines and Immunotherapies*

Edited by Zhongwu Guo and Geert-Jan Boons

*ABC Transporters and Multidrug Resistance*

Edited by Ahcène Boumendjel, Jean Boutonnat, and Jacques Robert

*Drug Design of Zinc-Enzyme Inhibitors: Functional, Structural, and Disease Applications*

Edited by Claudiu T. Supuran and Jean-Yves Winum

*Kinase Inhibitor Drugs*

Edited by Rongshi Li and Jeffrey A. Stafford

*Evaluation of Drug Candidates for Preclinical Development: Pharmacokinetics, Metabolism, Pharmaceutics, and Toxicology*

Edited by Chao Han, Charles B. Davis and Binghe Wang

*HIV-1 Integrase: Mechanism and Inhibitor Design*

Edited by Nouri Neamati

*Carbohydrate Recognition: Biological Problems, Methods, and Applications*

Edited by Binghe Wang and Geert-Jan Boons

*Chemosensors: Principles, Strategies, and Applications*

Edited by Binghe Wang and Eric V. Anslyn

*Medicinal Chemistry of Nucleic Acids*

Edited by Li He Zhang, Zhen Xi, and Jyoti Chattopadhyaya

*Plant Bioactives and Drug Discovery: Principles, Practice, and Perspectives*

Edited by Valdir Cechinel Filho

*Dendrimer-Based Drug Delivery Systems: From Theory to Practice*

Edited by Yiyun Cheng

*Cyclic-Nucleotide Phosphodiesterases in the Central Nervous System: From Biology to Drug Discovery*

Edited by Nicholas J. Brandon and Anthony R. West

*Drug Transporters: Molecular Characterization and Role in Drug Disposition, 2<sup>nd</sup> Edition*

Edited by Guofeng You and Marilyn E. Morris

*Drug Delivery: Principles and Applications, 2<sup>nd</sup> Edition*

Edited by Binghe Wang, Longqin Hu, and Teruna J. Siahaan

*Carbon Monoxide in Drug Discovery: Basics, Pharmacology, and Therapeutic Potential*

Edited by Binghe Wang and Leo E. Otterbein

*Drug Transporters: Molecular Characterization and Role in Drug Disposition, Third Edition*

Edited by Guofeng You and Marilyn E. Morris

*Hydrogen Sulfide: Chemical Biology Basics, Detection Methods, Therapeutic Applications, and Case Studies, First Edition*

Edited by Michael D. Pluth

*Nucleic Acids in Medicinal Chemistry and Chemical Biology: Drug Development and Clinical Applications, First Edition*

Edited by Lihe Zhang, Xinjing Tang, Zhen Xi, and Jyoti Chattopadhyaya

*Oral Bioavailability and Drug Delivery: From Basics to Advanced Concepts and Applications, First Edition*

Edited by Ming Hu and Xiaoling Li

# **Oral Bioavailability and Drug Delivery**

From Basics to Advanced Concepts and Applications

*Edited by*

*Ming Hu*

University of Houston, Houston, TX, USA

*Xiaoling Li*

University of the Pacific, TJ Long School of Pharmacy, Stockton, CA, USA

**WILEY**

Copyright © 2024 by John Wiley & Sons, Inc. All rights reserved.

Published by John Wiley & Sons, Inc., Hoboken, New Jersey.  
Published simultaneously in Canada.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, scanning, or otherwise, except as permitted under Section 107 or 108 of the 1976 United States Copyright Act, without either the prior written permission of the Publisher, or authorization through payment of the appropriate per-copy fee to the Copyright Clearance Center, Inc., 222 Rosewood Drive, Danvers, MA 01923, (978) 750-8400, fax (978) 750-4470, or on the web at [www.copyright.com](http://www.copyright.com). Requests to the Publisher for permission should be addressed to the Permissions Department, John Wiley & Sons, Inc., 111 River Street, Hoboken, NJ 07030, (201) 748-6011, fax (201) 748-6008, or online at <http://www.wiley.com/go/permission>.

Trademarks: Wiley and the Wiley logo are trademarks or registered trademarks of John Wiley & Sons, Inc. and/or its affiliates in the United States and other countries and may not be used without written permission. All other trademarks are the property of their respective owners. John Wiley & Sons, Inc. is not associated with any product or vendor mentioned in this book.

Limit of Liability/Disclaimer of Warranty: While the publisher and author have used their best efforts in preparing this book, they make no representations or warranties with respect to the accuracy or completeness of the contents of this book and specifically disclaim any implied warranties of merchantability or fitness for a particular purpose. No warranty may be created or extended by sales representatives or written sales materials. The advice and strategies contained herein may not be suitable for your situation. You should consult with a professional where appropriate. Further, readers should be aware that websites listed in this work may have changed or disappeared between when this work was written and when it is read. Neither the publisher nor authors shall be liable for any loss of profit or any other commercial damages, including but not limited to special, incidental, consequential, or other damages.

For general information on our other products and services or for technical support, please contact our Customer Care Department within the United States at (800) 762-2974, outside the United States at (317) 572-3993 or fax (317) 572-4002.

Wiley also publishes its books in a variety of electronic formats. Some content that appears in print may not be available in electronic formats. For more information about Wiley products, visit our web site at [www.wiley.com](http://www.wiley.com).

***Library of Congress Cataloging-in-Publication Data:***

Names: Hu, Ming, Ph. D., editor. | Li, Xiaoling, Ph. D., editor.  
Title: Oral Bioavailability and Drug Delivery : from basics to advanced concepts and applications / edited by Ming Hu and Xiaoling Li.  
Other titles: Wiley series in drug discovery and development.  
Description: Hoboken, New Jersey : John Wiley & Sons, Inc., [2024] | Series: Wiley series in drug discovery and development | Includes bibliographical references and index.  
Identifiers: LCCN 2023018561 (print) | LCCN 2023018562 (ebook) | ISBN 9781119660651 (cloth) | ISBN 9781119660668 (adobe pdf) | ISBN 9781119660682 (epub)  
Subjects: MESH: Biological Availability | Administration, Oral | Drug Development | Pharmacokinetics  
Classification: LCC RS420 (print) | LCC RS420 (ebook) | NLM QV 38 | DDC 615.1/9-dc23/eng/20230829  
LC record available at <https://lccn.loc.gov/2023018561>  
LC ebook record available at <https://lccn.loc.gov/2023018562>

Cover design: Wiley

Cover Images: © La Gorda/Shutterstock (Human digestive system); © Tridsanu Thopet/Shutterstock (falling capsules medication); © Dan Thornberg/Shutterstock (Basketball sitting on a rim with net); © Jenner Images/Getty Images (Falling white pills with one pink pill in mid air)

Set in 9.5/12.5pt STIXTwoText by Straive, Chennai, India

*Dedicated to*

*My parents, Bailing Li and Jie Hu, for giving me life*

*My grandmother, Yunzhi Su, for raising me*

*My wife, Xinghang Ma, and sons, Richard and Louis, for their unconditional love, encouragement, and understanding.*

*Xiaoling Li*

*Dedicated to*

*My parents, Zhengye Hu and Qihua Chang, for Their Encouragement and Praise*

*My wife, Yanping Wang, for Her Love and Companionship*

*My daughter and son, Vivian and William, for Becoming Great Adults*

*My grandchildren, Stella and Arthur, for Bringing Joy and Continuing the Legacy*

*Ming Hu*





## Contents

	<b>List of Contributors</b>	<i>xxix</i>
	<b>Foreword</b>	<i>xxxix</i>
	<b>Preface</b>	<i>xli</i>
<b>1</b>	<b>Barriers to Oral Bioavailability – An Overview</b>	<b>1</b>
	<i>Ming Hu and Xiaoling Li</i>	
1.1	Introduction	1
1.1.1	Physicochemical Factors	2
1.1.2	Biological Factors	2
1.1.3	Diet and Food Effects	3
1.1.4	Drug–Drug Interactions	4
1.1.5	Scientific Disciplines Involved	4
	References	4
<b>2</b>	<b>Solubility of Pharmaceutical Solids</b>	<b>5</b>
	<i>Pramila Sharma, Yi Gao, Heran Li, Bhaskara R. Jasti, Sanming Li, and Xiaoling Li</i>	
2.1	Introduction	5
2.2	Fundamentals of Solubility	6
2.2.1	Definition	6
2.2.2	Thermodynamics of Solubility	6
2.2.3	Solubility and Dissolution	8
2.2.4	Factors that Affect Solubility	9
2.2.4.1	Solute Factors	9
2.2.4.2	Solvent Factors	11
2.2.5	Pharmaceutically Relevant Solubility	14
2.2.5.1	Medium of Solubility Determination	15
2.2.5.2	<i>In Vitro</i> Solubility	16
2.2.5.3	Estimation of Solubility in the GI Tract	18
2.3	Solubility and Oral Bioavailability	19
2.4	Strategies to Improve Solubility	21
2.4.1	Formulation through Salt Formation	21
2.4.2	Formulation Through Amorphous Solid Dispersions	21
2.4.3	Formulation Through Lipid and Surfactant-Based Formulations	24
2.4.4	Formulation Through Other Approaches	24
2.5	Summary	24
	Abbreviations	25
	References	25
<b>3</b>	<b><i>In Vitro</i> Dissolution of Pharmaceutical Solids</b>	<b>31</b>
	<i>Tze Ning Hiew and Paul W.S. Heng</i>	
3.1	Dissolution Theory and Fundamentals	31
3.1.1	Background and Rationale	31
3.1.2	Why Dissolution Testing	31

3.1.3	Theoretical Concepts	32
3.1.4	Properties of the API	32
3.1.5	Examples of Techniques to Alter Dissolution Rate Based on the Dissolution Theory	33
3.1.5.1	Nanotechnology – Changing the Surface Area Term in the Equation	33
3.1.5.2	Solid Dispersions – Changing the Solubility Term in the Equation	33
3.2	Dissolution of Drug Products	34
3.2.1	Type of Dosage Forms and Common Dissolution Mechanisms	34
3.2.1.1	Immediate-Release Dosage Forms	34
3.2.1.2	Modified-Release Dosage Forms	35
3.2.2	Factors Affecting Dissolution	36
3.2.2.1	Drug and Excipient Properties	36
3.2.2.2	Drug Product Formulation and Processing Conditions	36
3.3	<i>In Vitro</i> Dissolution Methods for Ensuring Quality of Commercial Drug Products	36
3.3.1	Compendial Dissolution Apparatus	36
3.3.2	General Compendial Dissolution Conditions	37
3.4	<i>In Vitro</i> Dissolution Methods in Product Development	38
3.4.1	Intrinsic Dissolution Apparatus	38
3.4.2	Use of Non-Compendial Apparatus	38
3.4.2.1	Surface Dissolution Imager (SDI)	38
3.4.2.2	Small-Volume Apparatus	38
3.4.2.3	Other Non-Compendial Apparatus	38
3.4.3	Use of Non-Compendial Dissolution Media	39
3.4.4	Use of Non-Sink Conditions	40
3.5	Automation in Dissolution Testing and Prediction	40
3.5.1	Automated Sampling	40
3.5.2	<i>In Situ</i> Analysis	40
3.6	Conclusions	42
	References	42
<b>4</b>	<b>Biological and Physiological Features of the Gastrointestinal Tract Relevant to Oral Drug Absorption</b>	<b>47</b>
	<i>Paul C.L. Ho</i>	
4.1	Introduction	47
4.2	Biological Features of Gastrointestinal Tract	47
4.2.1	Absorption Pathways	48
4.2.1.1	Transcellular and Paracellular Absorption Pathways	48
4.2.1.2	Facilitated and Carrier-Mediated Absorption Pathways	49
4.2.2	Peyer's Patches	51
4.3	Physiological Features of Gastrointestinal Tract	51
4.3.1	pH of Gastrointestinal Fluids	51
4.3.2	Biliary Secretion	52
4.3.3	Gastrointestinal Microflora	52
4.3.4	Gastrointestinal Transit and Motility	53
4.3.4.1	Gastric Emptying Rate	53
4.3.4.2	Intestinal Motility	54
4.4	Other Physiological Factors	54
4.4.1	Age Effects	54
4.4.2	Gender Effects	55
4.5	Conclusion	56
	References	56
<b>5</b>	<b>Absorption of Drugs Via Passive Diffusion and Carrier-Mediated Pathways</b>	<b>61</b>
	<i>Amit Kokate, Jae H. Chang, and Miki S. Park</i>	
	Disclaimer	61
5.1	Introduction	61
5.2	Passive Diffusion	62

5.2.1	Passive Diffusion Described by Fick's First Law	63
5.2.2	Rate-Limiting Step in Intestinal Drug Absorption	64
5.2.2.1	Gastric-Emptying Rate-Limited Absorption	64
5.2.2.2	Perfusion Rate-Limited Absorption	64
5.2.2.3	Dissolution Rate-Limited Absorption	64
5.2.2.4	Diffusion/Permeability Rate-Limited Absorption	65
5.3	Carrier-Mediated Transport	67
5.3.1	Competitive, Noncompetitive, and Un-competitive Inhibition	69
5.4	Summary	75
	References	75
<b>6</b>	<b>Determinant Factors for Passive Absorption of Drugs</b>	<b>79</b>
	<i>Wei Zhu and Mikolaj Milewski</i>	
6.1	Introduction	79
6.2	Fundamentals of Drug Absorption	79
6.2.1	Gut Wall	79
6.2.2	Pathways of Absorption	80
6.2.2.1	Transcellular Pathway	80
6.2.2.2	Paracellular Pathway	81
6.2.2.3	Transporter-Mediated Pathway	81
6.2.2.4	Total Passive Permeation (Paracellular and Transcellular Pathways)	81
6.2.3	Driving Forces for Passive Absorption	82
6.2.3.1	Concentration Gradient	82
6.2.3.2	Pressure Gradient	82
6.3	Absorption Determining Factors	82
6.3.1	Physiological Factors	82
6.3.1.1	Gastric Emptying Time	82
6.3.1.2	Gastric pH	83
6.3.1.3	Intestinal Transit Times	83
6.3.2	Physicochemical Factors	83
6.3.2.1	Solubility	84
6.3.2.2	Permeability	84
6.3.2.3	"pH Partition Theory" and $pK_a$	84
6.3.2.4	Particle Size and Surface Area	84
6.3.2.5	Salt Form	85
6.3.2.6	Polymorphic Form and Amorphous API	85
6.3.2.7	Lipinski Rule of 5	85
6.3.3	Formulation Factors Affecting Oral Absorption	86
6.4	Rate Limiting Steps in Absorption and Prediction of Dosing Amount Absorbed	86
6.4.1	The Maximum Absorbable Dose (MAD)	87
6.4.2	Dose Number (Do), Absorption Number (An), and Dissolution Number (Dn)	87
6.4.3	Permeability Limited Absorption	87
6.4.4	Dissolution Rate Limited Absorption	87
6.4.5	Solubility-Permeability Limited Absorption	88
6.4.6	Estimation of the Fraction Absorbed (Fa) in General Cases	88
6.5	Overview of In Silico Prediction of Absorption and Pharmacokinetics for Oral Dosage Forms	88
6.6	Summary	89
	References	90
<b>7</b>	<b>Protein Binding and Drug Distribution</b>	<b>95</b>
	<i>HaiAn Zheng and Marcel Musteata</i>	
7.1	Introduction	95
7.2	Protein-Drug Binding in Plasma	95
7.3	Modeling of Binding Equilibria	97
7.3.1	Stoichiometric Model	97
7.3.2	Site-Oriented Model	98

7.3.3	Free Drug Fraction	98
7.4	Bioanalytical Methods for Studying Drug–Protein Binding	98
7.4.1	Outline of Bioanalytical Approaches	99
7.4.2	Affinity Chromatography	99
7.4.3	Solid Phase Microextraction	101
7.4.4	Ultrafiltration	101
7.4.5	Equilibrium Dialysis	103
7.4.6	Other Approaches	105
7.4.7	Alternatives to Determining Plasma Protein Binding	105
7.5	Impact of Drug–Protein Binding on Pharmacokinetic Parameters	105
7.5.1	Volume of Distribution	106
7.5.2	Clearance	106
7.5.3	Half-life	106
7.6	Physicochemical Factors that Affect Protein–Drug Binding and Drug Distribution	106
7.7	Physiological and Pathological Factors that Affect Protein–Drug Binding and Drug Distribution	107
	References	107
<b>8</b>	<b>Drug Transport Across the Placental Barrier</b>	<b>111</b>
	<i>Valentina Bryant, Mansi Shah, Jennifer Waltz, and Erik Rytting</i>	
8.1	Introduction	111
8.2	Pharmacokinetics of Drugs Administered During Pregnancy	111
8.2.1	Absorption	111
8.2.2	Distribution	111
8.2.3	Metabolism	112
8.2.4	Excretion	112
8.3	Placental Development and Structure	112
8.4	Functions of the Human Placenta	113
8.5	Mechanisms of Drug Transport Across the Placenta	114
8.5.1	Passive Diffusion	115
8.5.2	Facilitated Diffusion	115
8.5.3	Active Transport	116
8.5.4	Endocytosis	116
8.6	Mechanisms of Drug Metabolism Within the Placenta	116
8.7	Strategies to Alter Drug Transport Across the Placenta	117
8.8	Experimental Models of the Human Placenta	118
8.8.1	Animal Models	119
8.8.2	<i>Ex Vivo</i> Placental Perfusion	119
8.8.3	<i>In Vitro</i> Trophoblast Tissue Preparations	120
8.8.4	Primary Cells from Human Placenta	120
8.8.5	Continuous Cell Lines	120
8.8.6	Placenta-on-a-Chip	121
8.8.7	<i>In Silico</i> Models	121
	References	122
<b>9</b>	<b>Biopharmaceutics Classification System: Theory and Practice</b>	<b>131</b>
	<i>Mehul Mehta, Jayabharathi Vaidyanathan, and Lawrence Yu</i>	
9.1	Introduction	131
9.2	Theory	131
9.2.1	Bioavailability and Bioequivalence	131
9.2.2	Oral Drug Absorption Prediction	132
9.2.2.1	Plug Flow Model	132
9.2.2.2	Compartmental Absorption and Transit Model	132
9.2.3	Biopharmaceutics Classification System	133
9.3	BCS-based Biowaiver	134
9.4	BCS Waiver Case Studies	136

9.4.1	Case Study 1	136
9.4.1.1	Solubility	136
9.4.1.2	Permeability	136
9.4.1.3	Dissolution	136
9.4.2	Case Study 2	136
9.4.2.1	Solubility	136
9.4.2.2	Permeability	137
9.4.2.3	Dissolution	137
9.4.3	Case Study 3	137
9.4.3.1	Formulation	137
9.4.3.2	Solubility	137
9.4.3.3	Dissolution	138
9.5	BCS: Additional Regulatory Applications	138
9.6	Summary	138
	References	139
<b>10</b>	<b>Effects of Food on Drug Absorption</b>	<b>141</b>
	<i>Zhu Zhou, Venugopal P. Marasanapalle, Xiaoling Li, and Bhaskara R. Jasti</i>	
10.1	Introduction	141
10.1.1	Food–Drug Interactions (Food Effects) in Clinical Therapy and Drug Development	141
10.1.1.1	Regulatory Considerations of Food Effects	142
10.1.1.2	Food–Drug Interactions in Clinical Therapy	142
10.1.1.3	Positive, Negative, and No Food Effects	143
10.1.1.4	Absorption of Drugs	144
10.1.1.5	Metabolism and Transport in the Gastrointestinal Tract (see also Chapter 11)	144
10.1.1.6	Permeability in the Gastrointestinal Tract	145
10.1.1.7	Food-Induced Changes on Drug Bioavailability	145
10.2	Mechanisms of Food Effects	147
10.2.1	Factors Causing Positive Food Effects	147
10.2.2	Factors Causing Negative Food Effects	148
10.3	Prediction of Food Effects	149
10.4	Summary	149
	Abbreviations	150
	References	150
<b>11</b>	<b>Drug Metabolism in Gastrointestinal Tract</b>	<b>155</b>
	<i>Rashim Singh, Dinh Bui, and Ming Hu</i>	
11.1	Introduction	155
11.1.1	Gastrointestinal Tract (GIT) as Drug Disposition Organ	155
11.1.2	Drug-Metabolizing Enzymes in GIT	156
11.1.2.1	Enzymes for Phase I Metabolism	156
11.1.2.2	Enzymes for Phase II Metabolism	157
11.1.3	Regulation of Drug-Metabolizing Enzymes by Nuclear Receptors	159
11.1.4	Diseases Associated with Drug-Metabolizing Enzymes	160
11.2	Role of Intestinal Efflux Transporters in the Drug Disposition	161
11.2.1	Efflux Transporters in Intestine	161
11.2.1.1	P-gp	162
11.2.1.2	MRP2	163
11.2.1.3	BCRP	163
11.2.2	Regulation of Efflux Transporters by Nuclear Receptors (See Also Chapter 41)	163
11.3	Drug Metabolism–Transporter Coupling in Drug Disposition in GIT	163
11.3.1	Triple Recycling of Drugs	164
11.3.1.1	Enterohepatic Recycling	164
11.3.1.2	Enteric Recycling	165
11.3.1.3	Local Recycling	165
11.3.2	Theories of Drug Metabolism–Transporter Coupling	166

- 11.3.2.1 “Double Jeopardy” Theory 166
- 11.3.2.2 “Revolving Door” Theory 166
- 11.3.3 Features of Drug Metabolism–Transporter Coupling Process 167
- 11.3.4 Challenges in Delineating Drug Metabolism–Transporter Coupling Process 168
- 11.3.5 Drug–Drug Interactions due to Drug Metabolism–Transporter Coupling Process 168
- 11.4 Factors Affecting Intestinal Drug Metabolism 168
  - 11.4.1 Pharmacogenetics 168
    - 11.4.1.1 Phase I Enzymes 169
    - 11.4.1.2 Phase II Enzymes 169
  - 11.4.2 Diet and Environment 169
- 11.5 Biopharmaceutics Drug Disposition Classification System 170
- 11.6 Metabolism-Based Drug–Drug and Drug–Natural Product Interactions 171
  - 11.6.1 Drug–Drug Interaction 171
  - 11.6.2 Drug–Natural Product Interactions 172
- 11.7 Metabolic Interactions Between Gut Microbiome and Drugs in GIT 173
- 11.8 Metabolism-Based Xenobiotic-Induced Toxicity 174
- 11.9 GIT Metabolism-Based Drug-Designing and Lead Optimization in Drug Development 174
- 11.10 Summary 175
  - Abbreviations 176
  - References 176

## **12 Liver Drug Metabolism 189**

*Ritika Kurian, Leslie T. Steen, and Hongbing Wang*

- 12.1 Introduction 189
- 12.2 Hepatic Structure and Function 189
- 12.3 Phase I Drug Metabolism 191
  - 12.3.1 Cytochrome P450 191
    - 12.3.1.1 General Characteristics 191
    - 12.3.1.2 Biochemistry 191
    - 12.3.1.3 Nomenclature 194
    - 12.3.1.4 Induction 195
    - 12.3.1.5 Inhibition 197
  - 12.3.2 Additional Phase I Enzymes 198
    - 12.3.2.1 Flavin Monooxygenases 199
    - 12.3.2.2 Carboxylesterases Hydrolysis 199
    - 12.3.2.3 Epoxide Hydrolase 199
- 12.4 Phase II Drug Metabolism 199
  - 12.4.1 Glucuronidation 200
  - 12.4.2 Sulfation 202
  - 12.4.3 Glutathione 203
- 12.5 Novel Platforms for Drug Metabolism Studies 204
  - 12.5.1 Micropatterned Liver Cell Coculture 204
  - 12.5.2 Spheroids 205
  - 12.5.3 Liver on a Chip 205
- 12.6 Drug Metabolism and Its Impact on Adverse Drug Reactions 205
- 12.7 Conclusion 207
  - References 207

## **13 Urinary Excretion of Drugs and Drug Reabsorption 213**

*Jessica T. Babic, Jack Cook, and Vincent H. Tam*

- 13.1 Introduction 213
- 13.2 Kidney as an Eliminating Organ 213
  - 13.2.1 Glomerular Filtration 215
  - 13.2.2 Active Secretion 217
  - 13.2.3 Tubular Reabsorption 219
- 13.3 Drug Transporters and Their Role in Renal Elimination 220

13.3.1	Transporters Involved in Active Tubular Secretion	220
13.3.2	Transporters Involved in Reabsorption	221
13.3.3	Transporter-Mediated Drug-Drug Interactions (DDI)	221
13.4	Renal Elimination and Bioavailability	222
13.4.1	Urine Data Alone	222
13.4.2	Plasma and Urine Data Including Data from Intravenous Administration	224
13.4.3	Plasma and Urine Data Following Extravascular Administration	227
13.5	Augmented Renal Clearance	227
	References	228
<b>14</b>	<b>Excretion of Drugs and Their Metabolites into the Bile</b>	<b>233</b>
	<i>Song Gao, Imoh Etim, Robin Sunsong, Christabel Ebuzoeme, Ting Du, and Dinh Bui</i>	
14.1	Introduction	233
14.2	Anatomy and Physiology of the Liver and Biliary System	234
14.2.1	Anatomy of Liver and Biliary System	234
14.2.2	Physiological Function of Biliary Excretion	234
14.3	Biliary Excreted Drugs and Metabolites	235
14.4	Impact of Biliary Excretion on ADME and Pharmacokinetics	235
14.5	Hepatic Transporters Involved in Biliary Excretion	245
14.5.1	Uptake Transporters	246
14.5.1.1	Organic Anion Transporting Polypeptides (OATPs)	246
14.5.1.2	Organic Anion Transporters (OATs) and Organic Cation Transporters (OCTs)	247
14.5.1.3	Sodium/Taurocholate Cotransporting Polypeptide (NTCP)	247
14.5.2	Efflux Transporters	247
14.5.2.1	P-glycoprotein (P-gp)	247
14.5.2.2	Multidrug Resistance-associated Protein 2 (MRP2)	248
14.5.2.3	Breast Cancer Resistance Protein (BCRP)	248
14.6	Factors Affecting Biliary Secretion	248
14.6.1	Gender Variation in Biliary Excretion	248
14.6.2	Age Variation in Biliary Excretion	249
14.6.3	Other Factors Affect Biliary Excretion	250
14.7	Biliary Excretion Research Models	250
14.7.1	<i>In Vitro</i> Models	250
14.7.2	<i>In Situ</i> Perfusion with Bile Duct Cannulation in Rodents	253
14.7.3	<i>In Vivo</i> Animal Models	254
14.7.4	Models for Human Studies	254
14.8	Concluding Remarks	255
	Abbreviations	255
	References	255
<b>15</b>	<b>Pharmacokinetic Behaviors of Orally Administered Drugs</b>	<b>267</b>
	<i>Hamdah Al Nebaihi, Dion R. Brocks, Jaime A. Yáñez, Marcus Laird Forrest, and Neal M. Davies</i>	
	Objectives	267
15.1	Introduction	267
15.1.1	Orders of Reaction	267
15.1.1.1	Zero-Order Reaction	268
15.1.1.2	First-Order Reaction	269
15.1.2	Pharmacokinetic Models	269
15.1.2.1	Compartmental Models	270
15.1.2.2	Non-compartmental Model	271
15.1.3	Pharmacokinetics of Oral Administration	271
15.2	Physicochemical Factors Affecting Oral Concentration Time Profiles	274
15.2.1	Dissolution Rate Limited Absorption	274
15.2.2	Solubility-Limited Absorption	275
15.2.2.1	Modified Release Formulation	276
15.2.2.2	Nanocrystals	278

15.2.2.3	Cyclodextrins	279
15.2.2.4	Complexation: Formation of Poorly Absorbable Bile Salt Micelles	279
15.3	Physiological Factors Affecting Oral Concentration Time Profiles	281
15.3.1	Drug Metabolism	281
15.3.2	Enterohepatic Recycling	281
15.3.3	Gastric Emptying and Intestinal Transit Time	282
15.3.4	Chronopharmacokinetics	284
15.3.5	P-Glycoprotein and Other Transporters	285
15.3.6	Site-Specific Absorption	287
15.3.7	Genetic Polymorphism	288
15.3.8	Disease	291
15.3.8.1	Inflammation	291
15.3.8.2	Hepatic Disorders	293
15.3.8.3	Pain	294
15.3.9	Pregnancy	294
15.4	Food-Effects and Oral Concentration Time Profiles	296
15.4.1	Effects of Lipids	296
15.4.2	Effect of Citrus Juices	298
15.5	The Impact of the Lymphatic System on Oral Bioavailability	298
15.5.1	Overview of the Lymphatic System	298
15.5.2	Intestinal Lipoprotein Assembly	299
15.5.3	Integration of Drug with Intestinal Lymph	300
15.5.4	Assessment Tools for Intestinal Lymph Drug Transport	300
15.5.5	Interpretation of Oral Concentration-Time Profiles Attributable to Lymphatic Absorption	301
15.6	Summation	303
	Abbreviations	304
	References	304
<b>16</b>	<b><i>In Vitro-In Vivo</i> Correlations of Pharmaceutical Dosage Forms</b>	<b>315</b>
	<i>Deliang Zhou and Yihong Qiu</i>	
16.1	Introduction	315
16.2	Categories of <i>In Vitro-In Vivo</i> Correlations	316
16.3	Convolution and Deconvolution	317
16.3.1	Linear System, Convolution, and Deconvolution	317
16.3.2	Convolution Methods	318
16.3.2.1	Point-Area Method	318
16.3.2.2	Trapezoidal Method	319
16.3.3	Deconvolution Methods	320
16.3.3.1	Algebraic Approach	320
16.3.3.2	Mass Balance Approaches	320
16.3.3.3	Numerical Approaches	321
16.4	Development and Assessments of an IVIVC	321
16.4.1	Study Design and General Considerations	321
16.4.2	IVIVC Model Building	322
16.4.2.1	Level A Correlation	322
16.4.2.2	Level B Correlation	323
16.4.2.3	Level C Correlation	323
16.4.3	Model Validation	324
16.5	Applications of an IVIVC	324
16.5.1	Setting Dissolution Specifications	324
16.5.2	Waiver of <i>In Vivo</i> Bioavailability Studies	325
16.6	Challenges	325
16.7	Physiologically Based Biopharmaceutics Models (PBBM)	326
16.8	Summary	328
	References	329



<b>17</b>	<b>Advanced Concepts in Oral Bioavailability Research – An Overview</b>	<b>333</b>
	<i>Baojian Wu, Min Chen, and Ming Hu</i>	
	Abbreviations	336
	References	336
<b>18</b>	<b>Expression and Pharmaceutical Relevance of Intestinal Transporters</b>	<b>339</b>
	<i>Melanie A. Felmler, Michael Ng, and Annie Lee</i>	
18.1	Introduction	339
18.2	Intestinal Drug Transport	340
18.3	Uptake Transporters	341
18.3.1	Apical Sodium-Dependent Bile Acid Transporter (ASBT)	341
18.3.2	L-alpha Amino Acid Transporters (LATs) (see also Chapter 19)	341
18.3.3	Proton-Dependent Monocarboxylate Transporters (MCTs)	346
18.3.4	Sodium-Dependent Monocarboxylate Transporters (SMCT)	347
18.3.5	Organic Anion Transporting Polypeptides (OATPs)	348
18.3.6	Peptides Transporters (PepTs)	349
18.3.7	Organic Cation Transporters (OCTs)	349
18.4	Efflux Transporters	350
18.4.1	P-glycoprotein (Pgp)	350
18.4.2	Multidrug Resistance-associated Protein (MRP)	351
18.4.3	Breast Cancer Resistance Protein (BCRP)	352
18.4.4	Novel Organic Cation Transporters (OCTN)	352
18.5	Summary	353
	References	353
<b>19</b>	<b>Amino Acid Transporters</b>	<b>361</b>
	<i>Liping Wang, Xiaoyan Li, Mengdi Ying, Ming Hu, and Zhongqiu Liu</i>	
19.1	Introduction	361
19.2	Classification of Amino Acid Transporters and their Functions	364
19.2.1	System $y^+$	368
19.2.2	System $y^+L$	369
19.2.3	System L	369
19.2.4	System $x_c^-$	370
19.2.5	System $b^{0,+}$	370
19.2.6	System $B^{0,+}$	371
19.2.7	System A	371
19.2.8	System <i>asc</i>	371
19.2.9	System <i>ASC</i>	371
19.2.10	System N	371
19.2.11	System $X_{AG}^-$	372
19.2.12	System IMINO	372
19.3	Epithelial Amino Acid Transporters	372
19.3.1	Neutral Amino Acid Transporters in the Apical Membrane of Renal Epithelial Cells	372
19.3.2	Neutral Amino Acid Transporters in the Apical Membrane of Intestinal Epithelial Cells	373
19.3.3	Neutral Amino Acid Transporters in the Basolateral Membrane of Epithelial Cells	373
19.3.4	Transporters of Cationic Amino Acids and Cystine in the Apical Membrane of Renal Epithelial Cells	374
19.3.5	Transporters of Cationic Amino Acids and Cystine in the Apical Membrane of Intestinal Epithelial Cells	374
19.3.6	Transporters of Cationic Amino Acids and Cystine in the Basolateral Membrane of Epithelial Cells	375
19.3.7	Transporters of Anionic Amino Acids in the Apical Membrane of Renal Epithelial Cells	375
19.3.8	Transporters of Anionic Amino Acids in the Apical Membrane of Intestinal Epithelial Cells	375
19.3.9	Transporters of Anionic Amino Acids in the Basolateral Membrane of Epithelial Cells	376
19.3.10	Transporters of Imino Acids and Glycine in the Apical Membrane of Renal Epithelial Cells	376

19.3.11	Transporters of Imino Acids and Glycine in the Apical Membrane of Intestinal Epithelial Cells	376
19.3.12	Transporters of Imino Acids and Glycine in the Basolateral Membrane of Epithelial Cells	376
19.3.13	Transporters of $\beta$ -Amino Acids and Taurine in the Apical Membrane of Renal Epithelial Cells	377
19.3.14	Transporters of $\beta$ -amino Acids and Taurine in the Apical Membrane of Intestinal Epithelial Cells	377
19.3.15	Transporters of $\beta$ -amino Acids and Taurine in the Basolateral Membrane	377
19.3.16	Transporters of Amino-Acid-Like Drugs	377
19.3.16.1	Transporters for L-DOPA	377
19.3.16.2	Transporters for Melphalan	378
19.3.16.3	Transporters for Baclofen and Gabapentin	378
19.3.16.4	Transporters for Thyroxine and Triiodothyronine	378
19.4	Endothelial Amino Acid Transporters	378
19.4.1	Transporters in the Blood–Brain Barrier	378
19.4.2	Transporters for Human Fetal Endothelium	379
19.4.3	Transporters for Aortic Endothelium	380
19.4.4	Transporters for Pulmonary Endothelium	380
19.5	Regulation of Amino Acid Transport	380
19.5.1	Regulating Effects of Vasoactive Agonists	380
19.5.2	Regulation of Amino Acid Transport by Ischemia and Hypoxia	381
19.5.3	Regulation of Amino Acid Transport by Cytokines	382
19.6	Conclusion	382
	Abbreviations	382
	References	383

## 20 Drug Transporters and Their Role in Absorption and Disposition of Peptides and Peptide-Based Pharmaceuticals 393

*David J. Lindley, Stephen M. Carl, Dea Herrera-Ruiz, Li F. Pan, Lori B. Ward, Jonathan M.E. Goole, Olafur S. Gudmundsson, Matthew Behymer, and Gregory T. Knipp*

20.1	Introduction	393
20.1.1	Passive Permeability of Peptide and Peptide-Based Agents	395
20.1.2	General Transporter Overview	396
20.2	Transport Systems Mediating Peptide-based Pharmaceutical Absorption and Disposition: The Solute Carrier (SLC) Family	397
20.2.1	Proton-Coupled Oligopeptide Transporters (SLC15A)	397
20.2.2	Organic Anion/Cation Transporters (SLC21A/SLCO/SLC22A)	398
20.2.3	Monocarboxylate Transporters (SLC16A)	398
20.2.4	Non-SLC Member-Mediated Peptide Transport	399
20.3	ATP Binding Cassette (ABC) Transporters	399
20.3.1	P-glycoprotein (ABCB1) and Other ABCB Isoforms	399
20.3.2	Multidrug Resistance-Associated Protein Family (MRP; ABCC)	399
20.3.3	Breast Cancer Resistance Protein (BCRP, ABCG2)	400
20.4	Gastrointestinal Tract-Specific Transporter Activity	400
20.4.1	Solute Carrier (SLC) Family	400
20.4.2	ATP Binding Cassette (ABC) Family	402
20.4.3	<i>In Vitro/In Vivo</i> Case Studies: Utilizing Transport Systems for Drug Delivery	403
20.4.3.1	<i>In Vitro</i> Testing Methods	403
20.4.3.2	Defining Absorption Windows	403
20.4.3.3	Exploiting Influx Transporters	404
20.4.3.4	Overcoming Efflux Transporter Effects	404
20.4.3.5	Active Pharmaceutical Ingredient and Excipient Effects	405
20.4.3.6	Food–Drug Interactions	405
20.4.3.7	Drug–Drug Interactions	406
20.4.3.8	Pharmacogenomics	407
20.5	Conclusions	407
	Acknowledgments	408
	References	408

<b>21</b>	<b>OATP Transporters in Hepatic and Intestinal Uptake of Orally Administered Drugs</b>	<b>417</b>
	<i>Wei Yue, Taleah Farasyn, Alexandra Crowe, Khondoker Alam, Lucila Garcia-Contreras, Yifan Tu, and Lu Wang</i>	
21.1	Introduction	417
21.2	Hepatic OATP1B1 and OATP1B3	417
21.2.1	Substrate Transport Specificity and Transport Mechanism of OATP1B1 and OATP1B3	417
21.2.2	Altered Disposition of OATP1B1 and 1B3 Substrates Due to Genetic Variation	418
21.2.3	Altered Disposition of OATP1B1 and 1B3 Substrates Due to Drug–Drug Interactions	419
21.2.4	Model-Based Prediction of DDIs Mediated by OATP1B1 and OATP1B3	419
21.2.4.1	Static Model for the Prediction of OATP1B1- and OATP1B3-Mediated DDIs	419
21.2.4.2	Physiologically Based Pharmacokinetic (PBPK) Models for the Prediction of OATP1B1- and OATP1B3-Mediated DDIs	420
21.2.5	Factors Involved in Altered Transporter Function of OATP1B1 and OATP1B3	420
21.2.5.1	Transcriptional Regulation of OATP1B1 and OATP1B3	420
21.2.5.2	Posttranslational Regulation of OATP1B1 and OATP1B3	420
21.3	OATP2B1 in the Intestine	420
21.3.1	Substrates of OATP2B1	421
21.3.2	Altered Disposition of OATP2B1 Substrates Due to Genetic Variation	421
21.3.3	Altered Disposition of OATP2B1 Substrates Due to Food–Drug and Drug–Drug Interactions	421
21.3.4	Factors Involved in Altered Transporter Function of OATP2B1	421
21.4	OATP1A2 in the intestine	421
21.5	Summary	422
	Acknowledgement	422
	References	422
<b>22</b>	<b>ABC Transporters in Intestinal and Liver Efflux</b>	<b>429</b>
	<i>Marilyn E. Morris and Tianjing Ren</i>	
22.1	Introduction	429
22.2	Apical Membrane Efflux Proteins	430
22.2.1	ABCB1 (P-glycoprotein)	430
22.2.2	ABCB4 (MDR2/3)	431
22.2.3	ABCB11 (BSEP)	431
22.2.4	ABCC2 (MRP2)	441
22.2.5	ABCG2 (BCRP)	441
22.3	Basolateral/Lateral Membrane Efflux Proteins	442
22.3.1	ABCC1 (MRP1)	442
22.3.2	ABCC3 (MRP3)	442
22.3.3	ABCC4 (MRP4)	443
22.3.4	ABCC5 (MRP5)	443
22.3.5	ABCC6 (MRP6)	444
22.4	Clinical Relevance of ABC Transporters in Oral Bioavailability of Drugs	444
22.5	Pharmacogenomics of ABC Transporters	445
22.6	Regulation of Efflux Transporters	445
22.7	Summary	446
	Abbreviations	446
	Acknowledgments	447
	References	447
<b>23</b>	<b>Interplay Between Metabolic Enzymes and Transporters</b>	<b>455</b>
	<i>Zuoxu Xie, Lu Wang, Zicong Zheng, Yifan Tu, Yi Rong, Ming Hu, and Stephen Wang</i>	
23.1	Pathways and Functions of Drug Metabolic Enzymes and Transporters	455
23.1.1	Xenobiotics Metabolism Pathways	455
23.1.1.1	Phase I Xenobiotic Metabolism Pathways (see Also Chapters 11 and 12)	455
23.1.1.2	Phase II Xenobiotic Metabolism Pathways	456
23.1.2	Pathways of Drug Elimination	458
23.1.2.1	P-glycoprotein (see Also Chapter 22)	459
23.1.2.2	Multidrug-Resistance Associated Proteins (see Also Chapter 22)	459

- 23.1.2.3 Organic Anion Transporters (see Also Chapter 21) 461
- 23.1.2.4 Organic Anion Transporting Polypeptides 461
- 23.2 Interplay Between Metabolic Enzymes and Transporters 462
  - 23.2.1 What is Interplay or Coupling? 462
  - 23.2.2 Type of Interaction Among Metabolic Enzyme(s) and Transporter(s) 462
    - 23.2.2.1 Interaction Between Metabolic Enzyme(s) and Metabolic Enzyme(s) 462
    - 23.2.2.2 Interaction Between Metabolic Enzyme(s) and Transporter(s) 462
    - 23.2.2.3 Interaction Between Transporter(s) and Metabolic Enzyme(s) 462
    - 23.2.2.4 Interaction Between Transporter(s) and Transporter(s) 463
  - 23.2.3 Complexities of Coupling 463
  - 23.2.4 Double Jeopardy Theory 463
    - 23.2.4.1 Consequences of Disruption 463
  - 23.2.5 Revolving Doors Theory 464
    - 23.2.5.1 Mechanism Description 464
    - 23.2.5.2 Consequences of Disruption 464
  - 23.2.6 Enterohepatic Recycling and Hepatoenteric Recycling 464
    - 23.2.6.1 Mechanistic Description of EHR and HER 465
    - 23.2.6.2 Consequences of Disruption 467
- 23.3 Conclusion 467
- References 468
  
- 24 Systemic Versus Local Bioavailability Enabled by Recycling 473**  
*Yifan Tu, Lu Wang, and Ming Hu*
  - 24.1 Introduction 473
  - 24.2 Systemic Bioavailability 473
  - 24.3 Local Bioavailability 474
  - 24.4 Factors Affecting Bioavailability 474
  - 24.5 Enterohepatic Recycling (EHR) 475
  - 24.6 Hepatoenteric Recycling (HER) 479
  - 24.7 Enteroenteric Recycling (EER) 480
  - 24.8 Summary 480
  - References 480
  
- 25 Intestinal Microbiome and Its Impact on Metabolism and Safety of Drugs 483**  
*Xin Y. Chu and Paul C.L. Ho*
  - 25.1 Introduction 483
  - 25.2 Direct Metabolism by Intestinal Microbiome 483
    - 25.2.1 Conversion to Bioactive Metabolites 483
    - 25.2.2 Conversion to Inactive Metabolites 485
    - 25.2.3 Increase Bioavailability 486
    - 25.2.4 Decrease Bioavailability 486
    - 25.2.5 Production of Toxic Metabolites 487
  - 25.3 Indirect Mechanisms Affecting Drug Metabolism 489
    - 25.3.1 Alterations of Host Gene Expression Modulating Drug Metabolizing Enzymes and Transporters 489
    - 25.3.2 Competition for Host Enzymes with Microbial Metabolites 490
    - 25.3.3 Enzyme Induction/Inhibition by Microbial Metabolites 490
  - 25.4 Impact of Intestinal Microbiome on Drug Treatment in Clinical Practice 492
    - 25.4.1 Aminosalicylates 492
    - 25.4.2 Tacrolimus 492
    - 25.4.3 Digoxin 492
    - 25.4.4 Levodopa 492
  - 25.5 Conclusion and Future Perspectives 492
  - References 493

<b>26</b>	<b>Drug–Drug Interactions and Drug–Dietary Chemical Interactions</b>	<b>501</b>
	<i>Mengbi Yang, Yuanfeng Lyu, and Zhong Zuo</i>	
26.1	Introduction	501
26.2	Drug–Drug Interactions (DDIs)	501
26.2.1	Interactions Involved in Oral Absorption of Small Molecules	501
26.2.1.1	Alteration of pH in the GI Tract	501
26.2.1.2	Formation of Insoluble Complex in GI Tract	506
26.2.1.3	Modulation of Gastrointestinal Motility	506
26.2.1.4	Alteration of Intestinal Transporters	506
26.2.1.5	Alteration of Intestinal First-Pass Metabolism Via Interplay Between Metabolic Enzymes and Transporters (see also Chapter 23)	506
26.2.1.6	Alteration of Intestinal Microbiota (see also Chapter 25)	507
26.2.2	Pharmacokinetics Interactions Involving Liver Metabolic Enzymes	508
26.2.3	Pharmacokinetics Interactions Involving Transporters in Liver, Kidney, and Other Organs	508
26.2.4	Pharmacokinetics and Pharmacodynamics Interactions Between Drugs and Biologics	509
26.3	Drug–Dietary Chemical Interactions in Oral Bioavailability	510
26.3.1	Garlic	510
26.3.2	Pepper	516
26.3.3	St John’s Wort	516
26.3.4	Ginkgo Biloba	516
26.3.5	Curcumin and Curcuma Rhizomes Extract	516
26.3.6	Grapefruit Juice	517
26.3.7	Caffeine	517
26.3.8	Vitamins	517
26.4	Summary	517
	Abbreviations	517
	References	518
<b>27</b>	<b>Regulatory Considerations in Metabolism- and Transport-Based Drug Interactions</b>	<b>523</b>
	<i>Xinning Yang, Sue-Chih Lee, Xinyuan Zhang, and Lei Zhang</i>	
	Disclaimer	523
27.1	Overview of Drug–Drug Interactions	523
27.2	Regulatory Recommendations of DDI Studies	527
27.3	Highlights of the Final Guidances for Industry: <i>In Vitro</i> and Clinical Drug Interaction Studies – Cytochrome P450 Enzyme- and Transporter-Mediated Drug Interactions	528
27.3.1	Highlights Concerning Drug Metabolizing Enzyme-Based DDIs	528
27.3.1.1	Establishment of the NME’s Metabolic Profile and Determine Whether NME is a Substrate of a Particular CYP <i>In Vitro</i>	528
27.3.1.2	Criteria for Identifying an NME as a CYP Enzyme Inhibitor <i>In Vitro</i> and Determining Whether an <i>In Vivo</i> Study Should be Conducted	529
27.3.1.3	Evaluation of an NME as a Potential CYP Enzyme Inducer <i>In Vitro</i> and Determining Whether an <i>In Vivo</i> Study Should be Conducted	530
27.3.1.4	Metabolites as Substrates or Inhibitors for CYP Enzymes	533
27.3.1.5	Classification of CYP Enzyme Inhibitors, Inducers, and Substrates	534
27.3.1.6	Pharmacogenetic Considerations	535
27.3.1.7	Evaluation of Multiple CYP Inhibitors or Elimination Pathways may be Appropriate	535
27.3.1.8	Use of Cocktails for <i>In Vivo</i> Evaluation of an NME’s Drug Interaction Potential	535
27.3.2	Highlights Concerning Drug Transporter-Based DDIs	535
27.3.2.1	Clinically Important Transporters for Routine Evaluations During Drug Development	536
27.3.2.2	Mechanistic Approach in Transporter Studies	536
27.3.2.3	<i>In Vitro</i> Transporter Assay Systems and Assay Validation	536
27.3.2.4	<i>In Vitro</i> Evaluation of an Investigational Drug as a Transporter Substrate	536

27.3.2.5	<i>In Vitro</i> Evaluation of an Investigational Drug as a Transporter Modulator	538
27.3.3	Points to Consider for <i>In Vivo</i> Drug Interaction Study Design	541
27.3.3.1	Evaluation of a Drug as an Inhibitor or Inducer for CYPs	542
27.3.3.2	Evaluation of a Drug as a Substrate for CYPs	543
27.3.4	Issues to Consider in the Interpretation of Drug Interaction Study Results	544
27.4	Role of Physiologically Based Pharmacokinetic (PBPK) Modeling in DDI Assessment	544
27.5	A Labeling Example to Illustrate the Translation of Complicated Drug Interaction Results to Labeling: Tipranavir	547
27.5.1	Drug Interaction Potential Assessment during NDA Review	547
27.5.2	Labeling Impact	548
27.6	Examples to Illustrate the Use of PBPK in Supporting Labeling for Drugs that are Dual CYP3A/P-GP Substrates	549
27.7	Summary	549
	Acknowledgement	550
	References	550
<b>28</b>	<b>Formulation Approaches to Improve Oral Bioavailability of Drugs</b>	<b>559</b>
	<i>Zeren Wang, Chandan Bhugra, and Shun Chen</i>	
28.1	Introduction	559
28.1.1	Why NCEs in the Current Pipelines are Poorly Water Soluble	559
28.1.2	Issues Related to Poorly Water-Soluble Drugs	559
28.2	Theoretical Considerations for Formulation Development of Poorly Water-Soluble Drugs	560
28.2.1	Factors Affecting Solubility	560
28.2.1.1	Crystal Lattice Energy (High Melting Temperature)	560
28.2.1.2	Hydrophobic Effect (High Log <i>P</i> Values)	560
28.2.2	Definition of Poorly Water-Soluble Pharmaceutical Compounds	561
28.2.2.1	US Pharmacopeia	561
28.2.2.2	Biopharmaceutics Classification System	561
28.2.2.3	Time to Complete Dissolution of API Particles	561
28.2.2.4	MAD Theory	562
28.3	Formulation Considerations for the Development of Poorly Water-Soluble Drugs	563
28.3.1	Formulation Development Strategy to Reduce Oral Absorption Barrier	563
28.3.2	Formulation Approaches to Enhance the Rate of Dissolution	564
28.3.2.1	Hammer Milling	564
28.3.2.2	Micronization	565
28.3.3	Formulation Approaches to Enhance the Solubility in the GI Lumen	566
28.3.3.1	Salt Form Selection	566
28.3.3.2	Addition of Complexing Agents	566
28.3.3.3	Addition of pH Modifiers	567
28.3.3.4	Solid Dispersion Systems	567
28.4	Other Formulation Approaches	571
	References	571
<b>29</b>	<b>Lipid-Based and Self-Emulsifying Oral Drug Delivery Systems</b>	<b>575</b>
	<i>Pushkaraj Wagh, Jonathan Moreno, Christopher Nayar, and Jeffrey Wang</i>	
29.1	Introduction	575
29.2	Lipid-based Drug Delivery Systems	575
29.2.1	Liposomes	576
29.2.2	Proliposomes	579
29.2.3	Solid Lipid Nanoparticles	579
29.2.4	Lipid/Oil Suspensions	580
29.2.5	Emulsions	580
29.2.6	Self-Emulsifying Drug Delivery Systems (SEDDS) and Self-Microemulsifying Drug Delivery Systems (SMEDDS)	581

29.2.6.1	Components of SEDDS and SMEDDS	582
29.2.6.2	Characterization of SEDDS and SMEDDS	582
29.2.6.3	Examples of SEDDS and SMEDDS	584
29.2.6.4	Commercial SEDDS and SMEDDS products	586
29.3	Advantages and Limitations of Lipid-Based and Self-Emulsifying Drug Delivery Systems	586
29.4	Summary	586
	References	586
<b>30</b>	<b>Oral Delivery of Nanoparticles: Challenges and Opportunities</b>	<b>591</b>
	<i>Qing Lin, Ling Zhang, and Zhirong Zhang</i>	
30.1	Introduction	591
30.2	Role of Nanoparticle Shape, Size, and Surface in Oral Delivery of Nanoparticles	592
30.3	Characterization Methods of Nanoparticles for Oral Delivery	593
30.4	State-of-the-Art Carriers Designed and Applied in Oral Delivery of Nanoparticles	594
30.5	Challenges and Coexisting Opportunities	594
	References	595
<b>31</b>	<b>Oral Delivery of Therapeutic Peptides: Strategies for Product Development</b>	<b>599</b>
	<i>Puchun Liu</i>	
31.1	Introduction	599
31.2	Overview of Approaches to Enabling Oral Peptide Delivery	604
31.2.1	Protecting Peptides' Stability Against GIT Degradation Barriers	606
31.2.2	Enhancing Peptides' Permeability Across GIT Diffusion Barriers	606
31.2.3	Combining Techniques for both Stability and Permeability of Peptides	607
31.2.4	Optimizing Peptides' Structures for both Stability and Permeability	607
31.3	Observation and Data Analysis of Low BA with Large Variabilities	607
31.4	Recommended Strategies for Oral Peptide Product Development	609
31.4.1	Where is the Action Site? (distinguish systemic versus pre-systemic liver versus local GIT)	610
31.4.2	How Wide is the Therapeutic Window? (Ensure "Variable BA" not Efficacy/Safety Issue)	610
31.4.3	What is the Peptide's Structure? (Hope Cyclic-, Oligo- with Stable/Permeable Amino Acids)	610
31.4.4	Is the Technology Toolbox Good Enough? (Tackle Stability and Permeability Challenges)	611
31.4.5	Does it Worth? (Analyze "low BA" Cost in a Big Picture of Pharmacoeconomics)	611
	Abbreviations	613
	References	613
<b>32</b>	<b>Prodrugs to Improve Oral Delivery</b>	<b>619</b>
	<i>Arjun D. Patel, Shuchi Gupta, and Mamoun Alhamadsheh</i>	
32.1	Introduction	619
32.2	Factors Associated With Oral Drug Absorption	620
32.3	Intestinal Physiology and Background	620
32.4	Strategies to Improve the Bioavailability of Orally Administered Drugs	621
32.5	Prodrug Overview and Classification	622
32.6	Prodrug Strategies to Improve Aqueous Solubility	630
32.7	Prodrug Approaches for Enhancing Absorption	631
32.8	Prodrug Approaches for Targeting Enzymes	631
32.9	Prodrug Approaches for Targeting Membrane Transporters	632
32.9.1	Bile Acid Transporters	632
32.9.2	Monocarboxylic Acid Transporters	632
32.9.3	Nucleoside Transporters	632
32.9.4	Amino Acid Transporters	633
32.9.5	Peptide Transporters	633
32.10	Conclusion	633
	Abbreviations	634
	References	634

- 33 Gastroretentive Drug Delivery Systems 637**  
*Vrushali Waknis and Ajit S. Narang*
- 33.1 Introduction 637
  - 33.2 Oral Drug Delivery – Challenges and Opportunities 637
  - 33.3 Human Gastric Physiology Relevant to GRDDS Design 638
    - 33.3.1 Gastrointestinal Transit Times 638
    - 33.3.2 Physiology of Gastric Emptying 638
    - 33.3.3 Factors Impacting Gastric Emptying 639
    - 33.3.4 Interaction of Drug Bioavailability with Gastric Physiology 639
  - 33.4 Technologies 639
    - 33.4.1 Buoyant Systems 640
      - 33.4.1.1 Buoyant Tablets 640
      - 33.4.1.2 Buoyant Multiparticulates 641
    - 33.4.2 Expandable Devices 641
      - 33.4.2.1 Expandable Devices in Veterinary Medicine 641
      - 33.4.2.2 Expandable Devices in Human Medicine 642
      - 33.4.2.3 Expandable Buoyant Systems 642
    - 33.4.3 Swelling Systems 643
    - 33.4.4 Bioadhesive Systems 643
      - 33.4.4.1 Criteria and Challenges to Mucoadhesion 643
      - 33.4.4.2 Bioadhesive Tablets 644
      - 33.4.4.3 Bioadhesive Multiparticulates 645
      - 33.4.4.4 Bioadhesive Microdevices 645
  - 33.5 New Drug Development Considerations 645
    - 33.5.1 *In vitro* Development 646
    - 33.5.2 Preclinical Development 646
    - 33.5.3 Clinical Development 647
    - 33.5.4 Diagnostic Tools for Preclinical and Clinical Development 648
      - 33.5.4.1 Gamma Scintigraphy 648
      - 33.5.4.2 Radiology 648
      - 33.5.4.3 Magnetic Resonance Imaging (MRI) 648
      - 33.5.4.4 Ultrasound 648
      - 33.5.4.5 Gastroscopy 649
      - 33.5.4.6 Magnetic Marker Monitoring (MMM) 649
  - 33.6 Commercial GRDDS Products and Investigational New Products 649
    - 33.6.1 Acuform® 650
    - 33.6.2 Accordion Pill® (AP) 650
    - 33.6.3 Lyndra® 650
    - 33.6.4 Plenity® 650
    - 33.6.5 Geoclock® and Soctec® 653
  - 33.7 Future Outlook 653
- Acknowledgments 654  
References 654
- 34 Enhancing Oral Bioavailability Using 3D Printing Technology 657**  
*Timothy Tracy, Senping Cheng, Lei Wu, Xin Liu, and Xiaoling Li*
- 34.1 Introduction 657
  - 34.2 3D Printing in Pharmaceutical Applications 657
    - 34.2.1 Extrusion-Based Systems 658
    - 34.2.2 Powder-Based Systems 659
    - 34.2.3 Liquid-Based Systems 660
  - 34.3 Novel Tablet Structures Possible with 3D Printing 660
    - 34.3.1 Unique Tablet External Geometries 660
    - 34.3.2 Unique Tablet Internal Geometries 660



34.3.2.1	Layered Designs	661
34.3.2.2	Release Control Caps	662
34.3.2.3	Multiple Compartments	663
34.4	Application of 3D Printing in Oral Bioavailability Enhancement	663
34.4.1	3D Printing Combined with Solubility Enhancement Techniques (SEDDS, ASD, etc.)	663
34.4.2	Enhancing Bioavailability Through Controlling the Location of Drug Release	666
34.4.2.1	Gastro-Retention	666
34.4.2.2	Colon Targeting	670
34.4.3	Optimizing Drug Pharmacokinetics to Enhance Bioavailability	670
34.5	Future Outlook for 3D Printing and Bioavailability Enhancement	672
34.6	Summary	673
	References	673
<b>35</b>	<b>Anatomical and Physiological Factors Affecting Oral Drug Bioavailability in Rats, Dogs, Monkeys, and Humans</b>	<b>677</b>
	<i>Ayman El-Kattan</i>	
35.1	Introduction	677
35.2	Determinants of Oral Bioavailability	677
35.2.1	Absorption	677
35.2.2	Physiological Factors that Impact Oral Drug Absorption	677
35.2.2.2	Mechanism of Oral Absorption	681
35.2.2.3	Summary of Intestinal Transporters that Impacts Oral Drug Absorption	685
35.2.3	Metabolism	685
35.2.3.1	Cytochrome P450s	686
35.2.3.2	UGT	688
35.2.3.3	Aldehyde Oxidase	689
35.2.3.4	Species Differences in the First Pass Metabolism and its Impact on Oral Bioavailability	690
35.2.3.5	Summary of Physiological Factors that Impact Drug Metabolism	690
35.3	Summary	691
	References	691
<b>36</b>	<b>In Vivo Methods for Oral Bioavailability Studies</b>	<b>701</b>
	<i>Ana Ruiz-Garcia and Marival Bermejo</i>	
36.1	Introduction	701
36.2	Factors that Affect Oral Availability	701
36.2.1	Solubility and Permeability	703
36.2.2	Formulation	703
36.2.3	Metabolism	704
36.3	<i>In Vivo</i> Animal Techniques	706
36.3.1	Animal Use and The Three Rs Policy. Ethical Guidelines	706
36.4	Animals Used in Bioavailability Studies	706
36.5	General Considerations for Blood Sampling	708
36.6	Statistical Considerations for Data Handling. (AUC Calculations in Sparse Sampling Designs)	708
36.7	Practical Examples in Rat Model	709
36.7.1	Jugular Vein Cannulation	709
36.8	Intestinal Perfusion (see also Chapter 42)	710
36.9	Mathematical Considerations	711
	References	712
<b>37</b>	<b>Caco-2 Cell Culture Model for Oral Drug Absorption</b>	<b>715</b>
	<i>Kaustubh Kulkarni, Lu Wang, and Ming Hu</i>	
37.1	Introduction	715
37.1.1	Intestinal Anatomic Structures and Their Relationship to Caco-2 Cells	715

37.1.1.1	Anatomy of the Intestinal Cell	715
37.1.1.2	Mucosal Folds	716
37.1.1.3	Villi	716
37.1.1.4	Microvilli	716
37.1.2	Intestinal Absorption of Drugs	716
37.1.2.1	Transcellular/Paracellular Passive Diffusion	716
37.1.2.2	Carrier-Mediated Transport	716
37.1.2.3	Endocytosis	717
37.1.3	Intestinal Metabolism of Drugs	717
37.1.4	Rationale for Caco-2	717
37.2	Description	717
37.2.1	Caco-2 Cell	718
37.2.2	The Development of Caco-2 Model	718
37.2.3	Caco-2 Cell TC-7 Clone	718
37.2.4	Shorter Growth Time	719
37.3	Utility	719
37.3.1	Use in Absorption Screening	719
37.3.2	Use in Absorption Mechanism Determination	719
37.3.3	Use in Metabolism Studies	720
37.3.4	Use in Intestinal Excretion Studies	720
37.3.5	Other Uses	720
37.4	Recent Progress	720
37.4.1	Addition or Deletion of Genes	721
37.4.1.1	Addition of Genes	721
37.4.1.2	siRNA Technique	721
37.4.1.3	CRISPR/CAS9 Technique	721
37.4.2	Intestine-On-a-Chip	721
37.5	Significance of Caco-2 Cell Culture Model in Drug Discovery and Development	722
37.6	Example	722
37.6.1	Drug Transport Study	722
37.6.2	Data Analysis	725
37.7	Concluding Remarks	727
	References	727
<b>38</b>	<b>OATP Overexpressed Cells and Their Use in Drug Uptake Studies</b>	<b>729</b>
	<i>Lu Wang, Zuoxu Xie, Yifan Tu, and Ming Hu</i>	
38.1	Introduction to OATP Cell Assay	729
38.1.1	Importance and Application	729
38.1.2	Guidance from Regulatory Agencies on <i>in vitro</i> Studies	730
38.1.3	Commonly Used Cell Lines	730
38.1.4	Commonly Used <i>In Vitro</i> Substrates and Inhibitors	731
38.2	Materials	731
38.2.1	Chemicals and Reagents	731
38.2.2	Supplies and Equipment	731
38.3	Methods	731
38.3.1	Preoperative Preparations	731
38.3.1.1	Cell Preparation	731
38.3.1.2	Solution Preparation	731
38.3.2	Uptake Study	731
38.3.3	Preliminary Studies	732
38.4	Data Analysis	732
38.4.1	Calculation of $K_m$ and $V_{max}$ in Substrate Study	732
38.4.2	Calculation IC50 in Inhibition Study	733
38.5	Notes	733
	References	735

<b>39</b>	<b>Use of Human Intestinal and Hepatic Tissue Fractions and Microbiome as Models in Assessment of Drug Metabolism and its Impact on Oral Bioavailability</b>	<b>737</b>
	<i>Hani Zaher and George Zhang</i>	
39.1	Introduction	737
39.2	Gastrointestinal Tract and Absorption (see Also Chapter 5)	737
39.3	Mechanisms of Drug Absorption and Concept of Oral Bioavailability (see also Chapters 4–6)	738
39.4	Intestinal Metabolism and Oral Bioavailability (see Also Chapter 11)	739
39.5	<i>In Vitro</i> Systems Applied to Assess Intestinal Metabolism	740
39.5.1	Human Intestinal Microsomes	740
39.5.2	Human Intestinal S9 Fraction	741
39.5.3	Human Intestinal Mucosa and Enterocytes	741
39.5.4	EpiIntestinal Microtissues	742
39.6	<i>In Vitro</i> Systems Applied to Assess Human Hepatic First-Pass Metabolism (see Also Chapter 12)	743
39.6.1	Human Liver Microsomes	743
39.6.2	Human Liver S9 Fractions	743
39.6.3	Recombinant Enzymes	744
39.6.4	Human Hepatocytes	744
39.7	Long-Term Hepatocyte Culture and Slow Metabolizing Drug Candidate	745
39.7.1	Human Hepatocytes Relay Method	745
39.7.2	Human HepatoPac and H $\mu$ REL Hepatocyte Coculture	746
39.7.3	Human Hepatocytes Spheroid Cultures	747
39.8	Microbiome and Absorption: A New Perspective	747
39.9	Summary	748
	Acknowledgments	748
	Abbreviations	749
	References	749
<b>40</b>	<b>Liver Perfusion and Primary Hepatocytes for Studying Drug Metabolism and Metabolite Excretion</b>	<b>757</b>
	<i>Paresh P. Chothe, Sean Xiaochun Zhu, Sandeepraj Pusalkar, Chuang Lu, and Cindy Xia</i>	
40.1	Introduction	757
40.2	Liver Perfusion	758
40.2.1	The Technique	758
40.2.2	Scope	759
40.2.3	Utility of Liver Perfusion	759
40.2.3.1	Enzyme Systems and Metabolic Interactions	759
40.2.3.2	Effect of Protein Binding	761
40.2.3.3	Transporters	761
40.3	Primary Hepatocytes	762
40.3.1	Techniques	762
40.3.2	Scope	764
40.3.3	Utility of Primary Hepatocytes (see Also Chapter 39)	764
40.3.3.1	Transporter Studies	764
40.3.3.2	Enzymatic Studies	767
40.3.3.3	Drug Metabolism Studies	770
40.4	Organ Perfusion Versus Hepatocyte Studies	771
40.5	Perspectives	772
	Acknowledgements	772
	Abbreviations	772
	References	772
<b>41</b>	<b>Determination of Regulation of Drug Metabolizing Enzymes and Transporters</b>	<b>779</b>
	<i>Sergio C. Chai, Taosheng Chen, and Wen Xie</i>	
41.1	Introduction	779
41.2	In vivo Methods	779

41.2.1	Creation of Xenobiotic Receptor Mouse Models	779
41.2.1.1	Creation of PXR Knockout Mice	780
41.2.1.2	Creation of hPXR and CAR Transgenic Mice	780
41.2.1.3	Creation of hPXR “Humanized” Mice	780
41.2.2	Measurements of Expression of Drug-Metabolizing Enzymes in Animal Models	782
41.2.2.1	Detection of Enzyme Expression at the mRNA Level	782
41.2.2.2	Detection of Enzyme Expression at the Protein Level by Western Blot Analysis	783
41.2.2.3	Use of Xenobiotic Receptor Mouse Models for In vivo Drug Metabolism Studies	783
41.3	In vitro Methods	784
41.3.1	Reporter Gene	784
41.3.1.1	Plasmids	784
41.3.1.2	Transient Transfection of HepG2 Cells	784
41.3.1.3	Ligand Treatment	785
41.3.1.4	Luciferase and $\beta$ -galactosidase Assays	785
41.3.1.5	Data Analysis	785
41.3.2	Electrophoretic Mobility Shift Assay	785
41.3.2.1	Primer Design	785
41.3.2.2	Primer Annealing	785
41.3.2.3	Primer Labeling	787
41.3.2.4	Probe Purification	787
41.3.2.5	Preparation of an Acrylamide Gel	787
41.3.2.6	Preparation of In Vitro Synthesized NR Proteins	787
41.3.2.7	Binding Reaction	787
41.3.2.8	Gel Loading and Running	787
41.3.2.9	Gel Drying	787
41.3.2.10	Autoradiograph	788
41.3.3	Chromatin Immunoprecipitation (ChIP) Assay	788
41.3.3.1	Chromatin Crosslinking and Cell Lysis	788
41.3.3.2	Sonication to Shear DNA	788
41.3.3.3	Chromatin Immunoprecipitation and PCR Analysis	789
41.3.4	Measurement of Transporter Activity	789
41.3.5	Modulation of Cytochrome p450 Enzymes	789
41.4	Biochemical, Biophysical and Structural Analysis of NRs Using Purified Proteins	789
41.4.1	Protein Purification Strategies	789
41.4.1.1	Expression Vector	790
41.4.1.2	Protein Expression	790
41.4.1.3	Protein Purification	790
41.4.2	X-ray Crystallography	791
41.4.2.1	Crystallization of hPXR LBD	791
41.4.3	Time-Resolved Fluorescence Energy Transfer Assay	791
41.4.3.1	TR-FRET Assay to Monitor the Displacement of a Labeled Ligand from PXR	791
41.4.3.2	TR-FRET Assay to Monitor the Interaction of PXR with Coactivator or Corepressor Peptide	792
41.4.4	Protein Thermal Shift Assay	792
41.4.4.1	Monitoring Ligand-CAR Interactions by Protein Thermal Shift Assay	793
41.4.5	Tryptophan Fluorescence Quenching Assay	793
41.4.5.1	Ligand-PXR Interactions Monitored by Tryptophan Fluorescence Quenching Assay	793
41.4.6	Surface Plasmon Resonance	793
41.4.6.1	Probing Ligand Interactions to hCAR LBD by SPR	794
41.4.7	Absorbance-Based Assay to Monitor Ligand Binding to Cytochrome p450	794
41.4.8	High Throughput Screening Strategies to Identify Agonistic or Antagonistic PXR and CAR Ligands	794
41.4.8.1	Overview of HTS Campaigns	794
41.4.8.2	Chemical Library	795
41.4.8.3	Instrumentation in HTS	795
41.4.8.4	HTS Assay	795

41.4.8.5	Data Analysis	795
41.5	Conclusions	796
	Acknowledgments	796
	References	796
<b>42</b>	<b>Intestinal Perfusion Methods for Oral Drug Absorptions</b>	<b>801</b>
	<i>Li Li, Dinh Bui, Wei Zhu, and Eun-Jung (Zenobia) Jeong</i>	
42.1	Introduction	801
42.2	Application and Recent Development of the Intestinal Perfusion Method	801
42.2.1	Intestinal Regional Absorption Studies	801
42.2.2	Intestinal Metabolism Studies	802
42.2.3	Bile Duct Cannulation: Contribution of Intestine vs. Liver	802
42.2.4	Use of Inhibitors or Gene Knockout Animals	802
42.2.5	Intestinal Perfusion in Mice and Other Animals	803
42.3	Data Interpretation and Method Comparison	803
42.4	Common <i>In Vitro</i> Methods Studying Intestinal Permeability and Metabolism	803
42.4.1	Rat Subcellular Fractions (S9 Fractions and Microsomes)	803
42.4.2	Cultured Intestinal Cell Model	804
42.4.2.1	Caco-2 Cells and Caco-2 TC-7 Clone (see Also Chapter 37)	804
42.4.3	Animal Tissue-based <i>In Vitro</i> Method	805
42.4.3.1	Everted Sac	805
42.4.3.2	Ussing Chamber	805
42.4.4	Comparison and Relationship of Perfusion Model and Other Models for Studying Drug Metabolism and Absorption in Intestine	805
42.4.4.1	Intestinal Perfusion and Subcellular Fractions	805
42.4.4.2	Intestinal Perfusion and <i>In Vitro</i> Cell Line Model	806
42.4.4.3	Intestinal Perfusion and Ussing Chamber	806
42.4.5	Implication and Extrapolation of Animal Data in Predicting Human Intestinal Permeability	806
42.4.5.1	Human Intestinal Perfusion Method	806
42.4.5.2	Prediction of Human Intestinal Drug Absorption and Bioavailability with Animal Data	806
42.5	Summary	807
42.6	Methodologies and Experimental Data Analysis	807
42.6.1	Materials and Preparation Before Experiments	807
42.6.1.1	Chemicals	807
42.6.1.2	Reagents	808
42.6.1.3	Equipment	808
42.6.1.4	Other Materials	808
42.6.2	Animals	808
42.6.3	Experiment Procedure	808
42.6.3.1	Intestinal Perfusion Steps and Comments	808
42.6.3.2	Alternative Cannulation	811
42.6.4	Data Processing	811
42.6.4.1	Calculation of Drug Concentration in Blood, Perfusate, and Bile	811
42.6.4.2	Calculation of Permeability	811
42.6.4.3	Interpretation of Drug Concentration in Blood, Perfusate, and Bile	813
42.6.4.4	Interpretation of Permeability Data	813
	Acknowledgment	813
	References	815
<b>43</b>	<b>In Silico Prediction of Oral Drug Absorption</b>	<b>819</b>
	<i>Jin Dong, Zhu Zhou, Yujuan Zheng, and Miki Susanto Park</i>	
43.1	Introduction	819
43.2	QSPR Modeling	819
43.3	PBPK Modeling	821
43.4	PBBM Modeling as a Subset of PBPK Modeling	823
43.5	Applications of PBPK/PBBM Modeling	824

43.5.1	Establishing Safe Space Using Mechanistic Absorption Model	824
43.5.1.1	Bracketing Approach	824
43.5.1.2	Exposure–Response Analysis	824
43.5.1.3	<i>In Vitro–In Vitro</i> Correlation (IVIVC) (see also Chapter 16)	824
43.5.1.4	PBBM Based IVIVR	825
43.6	PBPK Software	827
43.6.1	Unique Features of GastroPlus	827
43.6.1.1	ACAT Model	827
43.6.1.2	IVIVCPlus Module	828
43.6.1.3	Lysosomal Trapping in Absorption and Drug Distribution	828
43.6.1.4	Case Studies	829
43.6.2	Unique Features of Simcyp Simulator	833
43.6.2.1	Case Study: The Impact of P-gp and CYP3A4 on drug Absorption DDIs for Bosutinib	835
43.6.2.2	Conclusion	838
43.7	Summary	839
	References	839
<b>44</b>	<b>Computational Modeling of Drug Oral Bioavailability</b>	<b>843</b>
	<i>Lon W.R. Fong, Beibei Huang, Rajan Chaudhari, and Shuxing Zhang</i>	
44.1	Introduction	843
44.2	Computational Modeling of Bioavailability	844
44.2.1	Qualitative Modeling	844
44.2.2	Quantitative Modeling	844
44.2.2.1	Physiologically Based Pharmacokinetic (PBPK) Modeling	844
44.2.2.2	Compartmental Absorption and Transit Model	846
44.2.2.3	Extensions of and Variations on the Compartmental Absorption and Transit Model	846
44.2.3	Statistical Modeling	848
44.2.3.1	Regression Analysis	850
44.2.3.2	Support Vector Machines	850
44.2.3.3	Decision Trees	850
44.2.3.4	Artificial Neural Networks	850
44.2.3.5	Other Algorithms	851
44.3	Conclusions	851
	Acknowledgment	852
	References	852
<b>45</b>	<b>Blood–Brain Barrier Permeability Assessment for Small-Molecule Drug Discovery Using Computational Techniques</b>	<b>857</b>
	<i>Yankang Jing and Xiang-Qun Xie</i>	
45.1	Introduction	857
45.2	Basic Principle of the BBB Permeation	857
45.3	Role of the BBB in Drug Delivery	858
45.4	Experimental Methods for Assessing BBB Permeability	858
45.5	Computational Method to Predict BBB Permeability	859
45.5.1	Commercial Software and Free Computational Tools for BBB Permeability Prediction	859
45.5.2	Rule-of-Thumb Methods for BBB Prediction	860
45.5.3	Traditional QSAR/QSPR to Predict log BB	861
45.5.4	Machine-Learning-Based Regression and Classification	863
45.5.5	Advance Deep Neural Network and Deep Learning for BBB Permeability	865
45.5.6	Summary and Discussion	866
	Abbreviations	867
	References	867
	<b>Index</b>	<b>871</b>